United States of America based
Genfit SA, a biopharmaceutical company, engages in the research and development of drugs for the prevention and treatment of cardiometabolic and neurodegenerative diseases. The company focuses on various therapeutic areas, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer's diseases. Its lead proprietary program, GFT505, is an oral drug candidate under Phase II clinical trial for the treatment of pre-diabetes/diabetes. The company's products also include AVE0897 and SLV341, which are in Phase I clinical trial for the treatment of diabetes; SLV342, a pre-clinical product for the treatment of atherosclerosis; SAVX1, a pre-clinical products for the treatment of diabetes and vascular inflammation; BMGFT02, a pre-clinical product for the treatment of pre-diabetes/diabetes and beta-cell failure; and BMGFT01, a pre-clinical stage product for the treatment of Atherosclerosis. It has various collaboration, partnership, and strategic agreements with Sanofi-Aventis, Solvay group, Servier, and Merck.
TechnologiesAI Companies (Drug Discovery)
A proprietary technology that underlies a novel, blood-based molecular biomarker test to rule in and/or rule out at-risk NASH (NAS ≥ 4 and F ≥ 2) in patients with at least one metabolic risk factor.1
NASH, the most severe form of NAFLD, is a highly underdiagnosed cause of severe liver complications- NAFLD is estimated to affect nearly 80 million people in the US, but only 5% are aware they have liver disease.1
No services posted yet